Following meetings with regulatory agencies in Europe and the US, Pledpharma has identified an opportunity to move Aladote directly to a registrational Phase II/III trial, expected to be initiated in mid-2020. We believe the valuation of Pledpharma continues to be attractive, and today’s announcement further supports the investment case, with two first-in-class late-stage assets that could be on the market within two to three years.